Goldman Sachs Group Inc. Makes New $533,000 Investment in Palvella Therapeutics, Inc. $PVLA

Key Points

• Goldman Sachs Group Inc. made a new investment of approximately $533,000 in Palvella Therapeutics, acquiring 19,053 shares in the first quarter.
• Analysts have set positive price targets for Palvella Therapeutics, with an average consensus target price of $65.91 and multiple institutions rating the stock as a "Buy" or "Outperform."
• Palvella Therapeutics reported a loss of ($0.86) earnings per share for the last quarter, missing consensus estimates, and analysts project annual EPS to be at ($3.69).

Goldman Sachs Group Inc. bought a new position in Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 19,053 shares of the company's stock, valued at approximately $533,000. Goldman Sachs Group Inc. owned 0.17% of Palvella Therapeutics at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Woodline Partners LP acquired a new position in Palvella Therapeutics during the 1st quarter worth approximately $5,435,000. Millennium Management LLC purchased a new stake in shares of Palvella Therapeutics during the first quarter valued at approximately $7,553,000. AWM Investment Company Inc. acquired a new position in shares of Palvella Therapeutics during the first quarter worth $1,943,000. Frazier Life Sciences Management L.P. boosted its stake in shares of Palvella Therapeutics by 5.5% in the first quarter. Frazier Life Sciences Management L.P. now owns 690,012 shares of the company's stock valued at $19,313,000 after purchasing an additional 36,120 shares during the period. Finally, Royce & Associates LP acquired a new stake in Palvella Therapeutics during the 1st quarter valued at $2,002,000. Institutional investors and hedge funds own 40.11% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on PVLA shares. Lifesci Capital assumed coverage on Palvella Therapeutics in a research note on Monday, August 4th. They set an "outperform" rating and a $90.00 price objective for the company. Chardan Capital raised their price target on shares of Palvella Therapeutics from $50.00 to $60.00 and gave the stock a "buy" rating in a research report on Friday, August 15th. Raymond James Financial set a $54.00 price target on shares of Palvella Therapeutics and gave the stock an "outperform" rating in a research note on Tuesday, August 5th. Truist Financial started coverage on shares of Palvella Therapeutics in a report on Monday, July 21st. They issued a "buy" rating and a $56.00 price target on the stock. Finally, Oppenheimer started coverage on shares of Palvella Therapeutics in a research report on Tuesday, September 9th. They issued an "outperform" rating and a $85.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating and eleven have issued a Buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $65.91.

Palvella Therapeutics Stock Down 2.0%

PVLA opened at $57.69 on Friday. The company's 50-day moving average price is $48.18 and its 200 day moving average price is $32.63. Palvella Therapeutics, Inc. has a fifty-two week low of $11.17 and a fifty-two week high of $63.12. The firm has a market cap of $638.05 million, a price-to-earnings ratio of -4.77 and a beta of -0.03.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.08). Research analysts anticipate that Palvella Therapeutics, Inc. will post -3.69 earnings per share for the current year.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.

Want to see what other hedge funds are holding PVLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.